Ajuba Overexpression Promotes Breast Cancer Chemoresistance and Glucose Uptake through TAZ-GLUT3/Survivin Pathway

Table 1

Distribution of Ajuba status in breast cancer according to clinicopathological characteristics.

Characteristics	Number of patients	Ajuba negative/low expression	Ajuba overexpression
Age
<60	73	35	38	0.3027
≥60	20	7	13
TNM stage
I	34	23	11	0.0009
II-IV	59	19	40
Tumor size
<2 cm	31	18	13	0.0771
≥2 cm	62	24	38
Lymph node metastasis
Absent	44	28	16	0.0007
Present	49	14	35
Estrogen receptor
Absent	30	12	18	0.4901
Present	63	30	33
Progesterone receptor
Absent	43	16	27	0.1530
Present	50	26	24
ErbB-2
Absent	66	26	40	0.0806
Present	27	16	11
Triple-negative
Absent	77	39	38	0.0196
Present	16	3	13